All In Biotech

Drug Trial Radar · NCT01170663

A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine

Last checked: Nov 20, 2026Latest source record: Sep 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 665 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

665

Actual

Start

Dec 2010

Primary completion

Jul 2013

Study completion Feb 2017

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Jul 27, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III randomized multicenter double-blind, placebo controlled trial evaluating the safety and efficacy of paclitaxel plus ramucirumab (IMC-1211B) drug product (DP) compared to paclitaxel plus placebo.

Conditions

  • Gastric Cancer

Interventions

  • Ramucirumab (IMC-1211B) DPBiological

    8 milligrams/kilogram (mg/kg) intravenous (IV) infusion on Days 1 and 15 of every 4-week cycle

  • PlaceboDrug

    Ramucirumab placebo IV infusion on Days 1 and 15 of every 4-week cycle

  • PaclitaxelDrug

    Paclitaxel 80 milligrams per square meter (mg/m²) IV infusion on Days 1, 8, and 15 of every 4-week cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival Time (OS)Time frame: Randomization up to 27.5 months

Locations

167 sites in 26 countries. Site status is shown where the registry gives one.

  • ImClone Investigational Site

    Burbank, California

  • ImClone Investigational Site

    Los Angeles, California

  • ImClone Investigational Site

    San Francisco, California

  • ImClone Investigational Site

    Jacksonville, Florida

  • ImClone Investigational Site

    Miramar, Florida

  • ImClone Investigational Site

    Atlanta, Georgia

  • ImClone Investigational Site

    Honolulu, Hawaii

  • ImClone Investigational Site

    East Orange, New Jersey

  • ImClone Investigational Site

    Albuquerque, New Mexico

  • ImClone Investigational Site

    New York, New York

  • ImClone Investigational Site

    Chattanooga, Tennessee

  • ImClone Investigational Site

    Houston, Texas

  • ImClone Investigational Site

    Seattle, Washington

  • ImClone Investigational Site

    Buenos Aires, Argentina

  • ImClone Investigational Site

    Caba, Argentina

  • ImClone Investigational Site

    Rosario, Argentina

  • ImClone Investigational Site

    Santa Fe, Argentina

  • ImClone Investigational Site

    Bankstown, New South Wales, Australia

  • ImClone Investigational Site

    Kogarah, New South Wales, Australia

  • ImClone Investigational Site

    Liverpool, New South Wales, Australia

  • ImClone Investigational Site

    Wollongong, New South Wales, Australia

  • ImClone Investigational Site

    Southport, Queensland, Australia

  • ImClone Investigational Site

    Kurralta Park, South Australia, Australia

  • ImClone Investigational Site

    Coburg, Victoria, Australia

  • ImClone Investigational Site

    Footscray, Victoria, Australia

  • ImClone Investigational Site

    Frankston, Victoria, Australia

  • ImClone Investigational Site

    Parkville, Victoria, Australia

  • ImClone Investigational Site

    Graz, Austria

  • ImClone Investigational Site

    Linz, Austria

  • ImClone Investigational Site

    Steyr, Austria

  • ImClone Investigational Site

    Vienna, Austria

  • ImClone Investigational Site

    Bonheiden, Belgium

  • ImClone Investigational Site

    Bruges, Belgium

  • ImClone Investigational Site

    Brussels, Belgium

  • ImClone Investigational Site

    Brussels, Belgium

  • ImClone Investigational Site

    Edegem, Belgium

  • ImClone Investigational Site

    Leuven, Belgium

  • ImClone Investigational Site

    Belo Horizonte, Brazil

  • ImClone Investigational Site

    Belo Horizonte, Brazil

  • ImClone Investigational Site

    Caxias do Sul, Brazil

Showing 40 of 167 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.